TARRYTOWN, N.Y. (Thomson Financial) - EpiCept Corp said new clinical data
have shown a durable improvement in leukemia-free survival over five years among
Acute Myeloid Leukemia (AML) patients who receive post-consolidation
immunotherapy with Ceplene (histamine dihydrochloride) in combination with low
dose interleukin-2.
Ceplene is currently under late stage review by the European Medicines
Evaluation Agency (EMEA).
"While the Phase III study of Ceplene was powered to show a leukemia-free
survival benefit over 36 months, these additional data provide confirmation of a
lasting leukemia-free benefit for at least five years," said Jack Talley,
President and CEO of EpiCept.
He added that Epicept remains on track to receive a final decision on
Ceplene by the European Commission during the first half of 2008.
tf.TFN-Europe_newsdesk@thomson.com
ak/ak
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|